Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 30;13(7):1532.
doi: 10.3390/microorganisms13071532.

Genetic Correlates of Synergy Mechanisms of Daptomycin Plus Fosfomycin in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus (MRSA)

Warren E Rose  1 , Selvi C Ersoy  2   3 , Wessam Abdelhady  2 , Alan R Dominguez  4 , Jedidiah Ndam Muyah Manna  4 , Jorge N Artaza  4 , Reetakshi Mishra  5 , Ahmed M Elsayed  2 , Richard A Proctor  6 , Sarah L Baines  7   8 , Benjamin P Howden  7   8 , Nagendra N Mishra  2   3
Affiliations

Genetic Correlates of Synergy Mechanisms of Daptomycin Plus Fosfomycin in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus (MRSA)

Warren E Rose et al. Microorganisms. .

Abstract

This study elucidates potential genetic determinants and mechanisms involved in the synergistic effects of daptomycin (DAP) + fosfomycin (FOF) combination therapy. Among 33 clinically derived DAP-susceptible (S)/DAP-resistant (R) isogenic strain pairs, mutations in the mprF gene occurred in 30/33 DAP-R strains, including polymorphisms of L826F (33%) or T345A/L/I (15%). Strain variants of DAP-S CB1483 serially passaged in vitro for 10 days in DAP +/- FOF identified a key non-synonymous mutation in mprF (L826F) only in the DAP monotherapy arm. Interestingly, passage in FOF alone or DAP + FOF prevented the emergence of this mprF mutation following 10-day passage. This L826F mprF polymorphism, associated with a "gain-in-function" phenotype, exhibited increased amounts of lysyl-phosphatidylglycerol (L-PG) in the cell membrane (CM). Transcriptomics revealed a relatively modest number (~10) of distinct genes that were significantly up- or downregulated (≥2 log fold) in both the DAP-S and DAP-R strain pairs upon DAP + FOF exposures (vs. DAP or FOF alone). Of note, DAP + FOF decreased expression of lrgAB and sdrE and increased the expression level of fosB. In a rabbit infective endocarditis (IE) model, the DAP-R CB185 strain treated with DAP +/- FOF showed significantly reduced lrgB expression in vegetations compared with DAP treatment alone. Overall, these findings indicate that DAP + FOF therapy impacts MRSA through multiple specific mechanisms, enhancing bacterial clearance.

Keywords: MRSA; combination therapy; daptomycin; fosfomycin; transcriptomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Venn diagram of genes altered ≥ 2-fold by DAP + FOF vs. DAP or FOF alone exposures in DAP-S/DAP-R MRSA strain pair. Red and black fonts indicate whether expression was increased (black) or decreased (red) by DAP + FOF exposure.
Figure 2
Figure 2
In vitro lrgB gene expression was significantly decreased in the DAP-S CB1483 and DAP-R CB185 MRSA strain pairs treated either with FOF alone or DAP + FOF vs. DAP alone treatment. * p < 0.05; ** p < 0.01 vs. DAP exposure.
Figure 3
Figure 3
In vivo lrgB gene expression was decreased in rabbit endocarditis vegetations of DAP-R CB185 treated either with FOF alone or DAP + FOF or control (untreated) vs. DAP alone. ** p < 0.01; *** p < 0.001 vs. DAP exposure.
See this image and copyright information in PMC

References

    1. Roch M., Gagetti P., Davis J., Ceriana P., Errecalde L., Corso A., Rosato A.E. Daptomycin resistance in clinical MRSA strains is associated with a high biological fitness cost. Front. Microbiol. 2017;8:2303. doi: 10.3389/fmicb.2017.02303. - DOI - PMC - PubMed
    1. Holland T.L., Cosgrove S.E., Doernberg S.B., Jenkins T.C., Turner N.A., Boucher H.W., Pavlov O., Titov I., Kosulnykov S., Atanasov B., et al. ERADICATE Study Group. Ceftobiprole for treatment of complicated staphylococcus aureus bacteremia. N. Engl. J. Med. 2023;389:1390–1401. doi: 10.1056/NEJMoa2300220. - DOI - PubMed
    1. Fowler V.G., Jr., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., Levine D.P., Chambers H.F., Tally F.P., Vigliani G.A., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 2006;355:653–665. doi: 10.1056/NEJMoa053783. - DOI - PubMed
    1. Rose W.E., Fallon M., Moran J.J., Vanderloo J.P. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: Influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression. Antimicrob. Agents Chemother. 2012;56:4422–4427. doi: 10.1128/AAC.00676-12. - DOI - PMC - PubMed
    1. Marty F.M., Yeh W.W., Wennersten C.B., Venkataraman L., Albano E., Alyea E.P., Gold H.S., Baden L.R., Pillai S.K. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. 2006;44:595–597. doi: 10.1128/JCM.44.2.595-597.2006. - DOI - PMC - PubMed

LinkOut - more resources